Oshawa, Canada

Dr James Cha

Stroke

Coronary Disease

Multiple Endocrine Neoplasia Type 1

Atrial Fibrillation

Hemorrhage

Thrombosis

Obesity

REGN9933

Apixaban

Semaglutide

REGN7508

Evolocumab

Amgen

Novo Nordisk

Regeneron Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation.

The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots.

The study is looking at several other research questions, including:

* What side effects may happen from taking REGN7508 or REGN9933
* How well do the study drugs reduce the risk of having a stroke
* How much of REGN7508 or REGN9933 is in the blood at different times
* Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Dr James Cha | Oshawa, Canada

Site insights

Work at this site?

Active trials

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (ROXI-ATLAS)

Trial sponsors